BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
66.61
-0.70 (-1.04%)
Sep 18, 2026, 4:00 PM EDT - Market closed
BridgeBio Pharma Employees
As of June 30, 2026, BridgeBio Pharma had 1,003 total employees, including 999 full-time and 4 part-time employees. The number of employees increased by 164 or 19.55% since the number was reported on December 31, 2025.
Employees
1,003
Change
164
Growth
19.55%
Revenue / Employee
$710,936
Profits / Employee
-$689,796
Market Cap
13.02B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1,003 | 164 | 19.55% | 999 | 4 |
| Dec 31, 2025 | 839 | 109 | 14.93% | 834 | 5 |
| Dec 31, 2024 | 730 | 174 | 31.29% | 725 | 5 |
| Dec 31, 2023 | 556 | 160 | 40.40% | 550 | 6 |
| Dec 31, 2022 | 396 | -182 | -31.49% | 392 | 4 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,000 |
| Jazz Pharmaceuticals | 2,890 |
| Axsome Therapeutics | 1,346 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| Twist Bioscience | 979 |
| Madrigal Pharmaceuticals | 915 |
BBIO News
- 2 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 days ago - BridgeBio Pharma Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 10 days ago - BridgeBio Pharma Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 11 days ago - BridgeBio Pharma Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 11 days ago - BridgeBio Pharma Slides: Corporate presentation - Filings
- 11 days ago - BridgeBio Pharma presents new exploratory analyses from PROPEL 3 at ESPE - TheFly
- 11 days ago - Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial - GlobeNewsWire
- 18 days ago - BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 - GlobeNewsWire